ISOPROTERENOL HYDROCHLORIDE- isoproterenol hydrochloride injection, solution

Nordic Pharma, Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ISOPROTERENOL HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for ISOPROTERENOL HYDROCHLORIDE INJECTION.			
ISOPROTERENOL HYDROCHLORIDE injection, for intravenous use Initial U.S. Approval: 1956 INDICATIONS AND USAGE			
 Isoproterenol hydrochloride injection is a beta-adrenergic agonist indicated: To improve hemodynamic status in patients in distributive shock and shock due to reduced cardiac output (1) For treatment of bronchospasm occurring during anesthesia (1) 			
DOSAGE AND ADMINISTRATION			
 Initiate isoproterenol hydrochloride injection at the lowest recommended dose and increase gradually based on patient response (2.2) 			
 Recommended initial dosage: Shock: 0.5 mcg to 5 mcg per minute as an intravenous infusion (2.2) Bronchospasm: 10 mcg to 20 mcg intravenous injection (2.2) 			
DOSAGE FORMS AND STRENGTHS Injection: 0.2 mg/mL and 1 mg/5 mL (0.2 mg/mL) single dose vial (3)			
CONTRAINDICATIONS Isoproterenol hydrochloride injection is contraindicated in patients with: • Tachycardia (4) • Ventricular arrhythmias (4) • Angina pectoris (4)			
 Cardiac arrhythmias and ischemia may be induced by isoproterenol hydrochloride injection (5.1) Sulfite: Isoproterenol hydrochloride injection contains metabisulfite, which may cause allergic reaction (5.2) 			
Common adverse reactions with isoproterenol include tachycardia and palpitations (6)			
To report SUSPECTED ADVERSE REACTIONS, contact Nordic Pharma, Inc. at 1-844-267-4641 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS			
Do not administer isoproterenol hydrochloride injection and epinephrine simultaneously due to			
 combined effects may induce serious arrhythmias (7) Concomitant use of tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium and certain antihistamines; hemodynamic parameters may potentiate a clinical response of isoproterenol 			
 (7) Beta-adrenergic blocking drugs may reduce cardiostimulating and bronchodilating effects of isoproterenol (7) 			
See 17 for PATIENT COUNSELING INFORMATION.			

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 General Considerations

2.2 Recommended Dosage

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Cardiac Arrhythmias and Ischemia

5.2 Allergic Reactions associated with Sulfite

6 ADVERSE REACTIONS

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

16 HOW SUPPLIED/STORAGE AND HANDLING

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Isoproterenol hydrochloride injection is indicated:

- To improve hemodynamic status in patients in distributive shock and shock due to reduced cardiac output
- For bronchospasm occurring during anesthesia

2 DOSAGE AND ADMINISTRATION

2.1 General Considerations

Inspect visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if the injection is pinkish or darker than slightly yellow or contains a precipitate. Discard any unused portion.

Diluted solution should be used immediately. Unused material should be discarded.

2.2 Recommended Dosage

Dosage should generally be started at the lowest recommended dose and increased gradually based on patient response.

Recommended dosage for adults with shock and hypoperfusion states:

Route of Administration	Preparation of Dilution [*] Infusion Rate [†]			
Intravenous infusion	Dilute 5 mL (1 mg) in 500 mL0.5 mcg to 5 mcg per			
	of 5%	minute (0.25 mL to 2.5 mL		
	Dextrose Injection, USP	of diluted solution)		

* Concentrations up to 10 times greater have been used when limitation of volume is essential.

+ Rates over 30 mcg per minute have been used in advanced stages of shock.

Adjust the rate of infusion based on heart rate, central venous pressure, systemic blood pressure, and urine flow. If the heart rate exceeds 110 beats per minute, consider decreasing or temporarily discontinuing the infusion.

Recommended dosage for adults with bronchospasm occurring during anesthesia:

Route of	Preparation of Dilution	Initial Dose	Subsequent
Administration			Dose
Bolus intravenous injection	Dilute 1 mL (0.2 mg) to 10 mL with Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP	(0.5 mL to 1 mL	The initial dose may be repeated when necessary

There are no well-controlled studies in children to establish appropriate dosing; however, the American Heart Association recommends an initial infusion rate of 0.1 mcg/kg/min, with the usual range being 0.1 mcg/kg/min to 1 mcg/kg/min.

3 DOSAGE FORMS AND STRENGTHS

Injection solution: single dose, clear glass vials containing isoproterenol in a clear, colorless solution;

- 1 mL containing 0.2 mg/1 mL (0.2 mg/mL)
- 5 mL containing 1 mg/5 mL (0.2 mg/mL)

4 CONTRAINDICATIONS

Isoproterenol hydrochloride injection is contraindicated in patients with:

- tachycardia
- ventricular arrhythmias
- angina pectoris

5 WARNINGS AND PRECAUTIONS

5.1 Cardiac Arrhythmias and Ischemia

Isoproterenol may induce cardiac arrhythmias and myocardial ischemia in patients, especially patients with coronary artery disease, or cardiomyopathy.

5.2 Allergic Reactions associated with Sulfite

Isoproterenol hydrochloride injection contains sodium metabisulfite, which may cause mild to severe allergic reactions including anaphylaxis or asthmatic episodes, particularly in patients with a history of allergies. However, the presence of metabisulfite in this product should not preclude its use for treatment in emergency situations, even if the patient is sulfite-sensitive, as the alternatives to using isoproterenol in a life-threatening situation may not be satisfactory.

6 ADVERSE REACTIONS

The following adverse reactions have been associated with use of isoproterenol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.

Nervous system disorders: Nervousness, headache, dizziness, visual blurring

Cardiovascular: Tachycardia, tachyarrhythmias, palpitations, angina, ventricular arrhythmias, Adams-Stokes attacks, pulmonary edema

Respiratory: Dyspnea

Other: Flushing of the skin, sweating, mild tremors, pallor, nausea

7 DRUG INTERACTIONS

Table 1. Clinically Relevant Interactions with Isoproterenol

Epinephrine	
Clinical	Both drugs are direct cardiac stimulants, and their combined effects may
Impact	induce serious arrhythmias upon simultaneous administration.
Intervention	Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously.
Drugs that r	nay potentiate clinical response of Isoproterenol
Impact	The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxinesodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine.
Intervention	Monitor hemodynamic parameters in patients who concurrently are taking tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium and certain antihistamines. Adjust doses appropriately.
Drugs that r	nay reduce clinical response of Isoproterenol

Clinical	The cardiostimulating and bronchodilating effects of isoproterenol are
Impact	antagonized by beta-adrenergic blocking drugs, such as propranolol.
Intervention	Monitor for hemodynamic response and relief of bronchospasm and adjust dose appropriately.
	aujust dose appi opi lately.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

<u>Risk Summary</u>

Prolonged experience with isoproterenol use in pregnant women over several decades, based on published literature, do not identify a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. However, there are risks to the mother and fetus associated with isoproterenol use during labor or delivery (*see Clinical Considerations*).

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the United States general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations

Hypotension associated with shock is a medical emergency in pregnancy which can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with shock may increase the risk of maternal and fetal morbidity and mortality. Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of isoproterenol on the fetus.

Labor and Delivery

Isoproterenol usually inhibits spontaneous or oxytocin induced contractions of the pregnant human uterus and may delay the second stage of labor. Avoid isoproterenol during the second stage of labor. Avoid isoproterenol in obstetrics when maternal blood pressure exceeds 130/80 mmHg.

Although isoproterenol may improve maternal hypotension associated with shock, it may result in uterine vasoconstriction, decreased uterine blood flow, uterine atony with hemorrhage, and fetal anoxia.

8.2 Lactation

<u>Risk Summary</u>

There is no information regarding the presence of isoproterenol in milk or the effects of isoproterenol on the breastfed infant or on milk production. However, due to its short half-life, isoproterenol exposure is expected to be very low in the breastfed infant.

8.4 Pediatric Use

Safety and efficacy of isoproterenol in pediatric patients have not been established.

Intravenous infusions of isoproterenol in refractory asthmatic children at rates of 0.05-

2.7 µg/kg/min have caused clinical deterioration, myocardial necrosis, congestive heart failure and death. The risks of cardiac toxicity appear to be increased by some factors [acidosis, hypoxemia, coadministration of corticosteroids, coadministration of methylxanthines (theophylline, theobromine) or aminophylline] that are especially likely to be present in these patients. If I.V. isoproterenol is used in children with refractory asthma, patient monitoring must include continuous assessment of vital signs, frequent electrocardiography, and daily measurements of cardiac enzymes, including CPK-MB.

8.5 Geriatric Use

Clinical studies of isoproterenol hydrochloride injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects in clinical circumstances. There are, however, some data that suggest that elderly healthy or hypertensive patients are less responsive to beta-adrenergic stimulation than are younger subjects. In general, dose selection for elderly patients should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant diseases or other drug therapy.

10 OVERDOSAGE


Overdosage of isoproterenol can cause tachycardia or other arrhythmias, palpitations, angina, hypotension, or hypertension. In case of overdosage, reduce the rate of administration or discontinue isoproterenol hydrochloride injection until patient's condition stabilizes. Monitor blood pressure, pulse, respiration, and EKG.

It is not known whether isoproterenol hydrochloride is dialyzable.

11 DESCRIPTION

Isoproterenol hydrochloride, USP is 3,4-Dihydroxy- α -[(isopropylamino)methyl] benzyl alcohol hydrochloride, a synthetic sympathomimetic amine that is structurally related to epinephrine but acts almost exclusively on beta receptors. The molecular formula is C₁₁H₁₇NO₃ • HCl. It has a molecular weight of 247.72 and the following structural formula:

Isoproterenol hydrochloride, USP is a racemic compound.



Each milliliter of the sterile solution contains:	
Isoproterenol Hydrochloride, USP	0.2 mg
Edetate Disodium (EDTA)	0.2 mg
Sodium Chloride	7.0 mg
Sodium Citrate, Dihydrate	2.07 mg
Citric Acid, Anhydrous	2.5 mg
Water for Injection	1.0 mL

The pH is adjusted between 2.5 and 4.5 with hydrochloric acid or sodium hydroxide.

The sterile solution is nonpyrogenic and can be administered by the intravenous, intramuscular, subcutaneous, or intracardiac routes.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Isoproterenol is a potent nonselective beta-adrenergic agonist with very low affinity for alpha-adrenergic receptors.

12.2 Pharmacodynamics

Intravenous infusion of isoproterenol in man lowers peripheral vascular resistance, primarily in skeletal muscle but also in renal and mesenteric vascular beds. Diastolic pressure falls. Renal blood flow is decreased in normotensive subjects but is increased markedly in shock. Systolic blood pressure may remain unchanged or rise, although mean arterial pressure typically falls. Cardiac output is increased because of the positive inotropic and chronotropic effects of the drug in the face of diminished peripheral vascular resistance.

Isoproterenol relaxes almost all varieties of smooth muscle when the tone is high, but this action is most pronounced on bronchial and gastrointestinal smooth muscle. It prevents or relieves bronchoconstriction, but tolerance to this effect develops with overuse of the drug.

In man, isoproterenol causes less hyperglycemia than does epinephrine. Isoproterenol and epinephrine are equally effective in stimulating the release of free fatty acids and energy production.

12.3 Pharmacokinetics

<u>Absorption</u>

Isoproterenol is readily absorbed when given parenterally or as an aerosol.

<u>Elimination</u>

Isoproterenol is metabolized primarily in the liver and other tissues by COMT. Isoproterenol is a relatively poor substrate for MAO and is not taken up by sympathetic neurons to the same extent as are epinephrine and norepinephrine. The duration of action of isoproterenol may therefore be longer than that of epinephrine but is still brief.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals to evaluate the carcinogenic potential of isoproterenol hydrochloride have not been done. Mutagenic potential and effect on fertility have not been determined. There is no evidence from human experience that isoproterenol hydrochloride injection may be carcinogenic or mutagenic or that it impairs fertility.

16 HOW SUPPLIED/STORAGE AND HANDLING

Isoproterenol hydrochloride injection, USP 0.2 mg/mL and 1 mg/5 mL is supplied as a sterile, clear, colorless solution free from visible particulate matter in 3 mL and 5 mL single-dose glass vials respectively.

NDC	Container	Concentration	Fill	Quantity
69918-731-10	Single-Dose Vial	0.2 mg/mL	1 mL	Carton of 10 Single-Dose Vials
69918-735-10	Single-Dose Vial	1 mg/5 mL (0.2 mg/mL)	5 mL	Carton of 10 Single-Dose Vials

Protect from light. Keep in opaque container until used.

Store at 20^o to 25^oC (68^o to 77^oF) [See USP Controlled Room Temperature].

Do not use if the injection is pinkish or darker than slightly yellow or contains a precipitate.

Discard unused portion.

Manufactured for:

Nordic Pharma, Inc. Berwyn, PA 19312 USA www.nordicpharmausa.com



The Nordic Pharma Logo is a trademark of Nordic Group B.V.

Manufactured by:

Indoco Remedies Limited Verna, Goa, 403722, India

Origin India

Revised: 04/2024

2011016

PRINCIPAL DISPLAY PANEL - ISOPROTERENOL HYDROCHLORIDE INJECTION LABELS

NDC 69918-731-01

Rx Only

Isoproterenol HCI Injection, USP

0.2 mg/mL

Protect from light.

Nordic Pharma, Inc.

Rev 04/2024



NDC 69918-731-10

Rx Only

Isoproterenol Hydrochloride Injection, USP

0.2 mg/mL

Intravenous, Subcutaneous, Intramuscular or Intracardiac Use Only

10 x 1 mL Single-Dose Vials



NDC 69918-735-01

Rx Only

Isoproterenol HCI Injection, USP

1 mg/5 mL (0.2 mg/mL)

Intravenous, Subcutaneous, Intramuscular or Intracardiac Use Only

Protect from light. See package insert.

Manufactured for: Nordic Pharma, Inc. Berwyn, PA 19312

5 mL Single-Dose Vial

Rev 04/2024



Isoproterenol Hydrochloride Injection, USP

1 mg/5 mL (0.2 mg/mL)

Intravenous, Subcutaneous, Intramuscular or Intracardiac Use Only

10 x 5 mL Single-Dose Vials



ISOPROTERENOL HY	DROCHLORIDE			
soproterenol hydrochloride i	njection, solution			
Product Information				
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source)			NDC:69918 731	
Route of Administration INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRACARDIAC				
Active Ingredient/Active	Moiety			
Ingre	dient Name	Basis	of Strength	Strength
			0.2 mg in 1 mL	
Inactive Ingredients				
	Ingredient Name		Stre	ngth
EDETATE DISODIUM (UNII: 7FLD91C86K)			0.2 mg in 1 n	۱L
SODIUM CHLORIDE (UNII: 451W47IQ8X)			7.0 mg in 1 n	۱L
TRISODIUM CITRATE DIHYDRATE (UNII: B22547B95K)			2.07 mg in 1	ml

AN	ANHYDROUS CITRIC ACID (UNII: XF417D3PSL) 2.5 mg in 1 mL						
WATER (UNII: 059QF0K00R)							
ΗY	DROCHLORIC	ACID (UNII: QTT17582CB)					
so	DIUM HYDRO	(IDE (UNII: 55X04QC32I)					
Pa	ackaging						
#	ltem Code	Package Description	Marketing St Date	tart Marketing End Date			
1	NDC:69918- 731-10	10 in 1 CARTON	08/01/2021				
1		1 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product					
Μ	arketing	Information					
	Marketing Category	Application Number or Monograph Citation	Marketing Sta Date	art Marketing End Date			
AN	DA	ANDA211237	08/01/2021				

	injection, solution				
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG		tem Code Source)	NDC:69918 735	
Route of Administration	INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRACARDIAC				
Active Ingredient/Active	e Moiety				
Ingr	edient Name	Basis	of Strength	Strength	
ISOPROTERENOL HYDROCHLO - UNII:L628TT009W)	RIDE (UNII: DIA2A74855) (ISOPROTERENOL	ISOPROTER HYDROCHL		0.2 mg in 1 mL	
Inactive Ingredients					
	Ingredient Name		Stre	ngth	
EDETATE DISODIUM (UNII: 7FLC	091C86K)		0.2 mg in 1 n	nL	
SODIUM CHLORIDE (UNII: 451W	47IQ8X)		7.0 mg in 1 n	nL	
TRISODIUM CITRATE DIHYDRA	TE (UNII: B22547B95K)		2.07 mg in 1	mL	
ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)				nL	
WATER (UNII: 059QF0K00R)					
HYDROCHLORIC ACID (UNII: QTT17582CB)					
TI DROCHLORIC ACID (ONII. QI	SODIUM HYDROXIDE (UNII: 55X04QC32I)				

Pa	Packaging					
#	ltem Code	Package DescriptionMarketing StartMarketingDateDateDate				
1	NDC:69918- 735-10	10 in 1 CARTON	08/01/2021			
1	5 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product					
Μ	larketing	Information				
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date						
			-			

Labeler - Nordic Pharma, Inc. (079843051)

Establishment				
Name	Address	ID/FEI	Business Operations	
Indoco Remedies Limited		915851870	analysis(69918-731, 69918-735) , manufacture(69918-731, 69918-735)	

Revised: 6/2024

Nordic Pharma, Inc.